Midkine in plasma as a novel breast cancer marker

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1735-1739

  Ibusuki, Mutsuko ^a   Fujimori, Hiromi ^a   Yamamoto, Yutaka ^a   Ota, Kazutoshi ^a   Ueda, Mitsuharu ^a   Shinriki, Satoru ^a   Taketomi, Masahiro ^b   Sakuma, Sadatoshi ^b   Shinohara, Masanori ^a   Iwase, Hirotaka ^a   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Cell Signals Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MDK PROTEIN, HUMAN; MUCIN 1; NERVE GROWTH FACTOR; TUMOR MARKER;

ARTICLE; BLOOD; BREAST; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

BREAST; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MUCIN-1; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70149115647     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01233.x     Document Type: Article

References (47)

1. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-1318.
2. Matsubara S, Tomomura M, Kadomatsu K, Muramatsu T. Structure of a retinoic acid-responsive gene, MK, which is transiently activated during the differentiation of embryonal carcinoma cells and the mid-gestation period of mouse embryogenesis. J Biol Chem 1990; 265: 9441-9443.
3. Kaname T, Kuwano A, Murano I et al. Midkine gene (MDK), a gene for prenatal differentiation and neuroregulation, maps to band 11p11.2 by fluorescence in situ hybridization. Genomics 1993; 17: 514-515.
4. Murasugi A, Tohma-Aiba Y. Production of native recombinant human midkine in the yeast, Pichia pastoris. Protein Expr Purif 2003; 27: 244-252.
5. Mitsiadis TA, Muramatsu T, Muramatsu H, Thesleff I. Midkine (MK), ahe parin-binding growth/differentiation factor, is regulated by retinoic acid and epithelial-mesenchymal interactions in the developing mouse tooth, and affects cell proliferation and morphogenesis. J Cell Biol 1995; 129: 267-281.
6. Toriyama K, Muramatsu H, Hoshino T, Torii S, Muramatsu T. Evaluation of heparin-binding growth factors in rescuing morphogenesis of heparitinasetreated mouse embryonic lung explants. Differentiation 1997; 61: 161-167.
7. Sakurai H, Bush KT, Nigam SK. Identification of pleiotrophin as a mesenchymal factor involved in ureteric bud branching morphogenesis. Development 2001; 128: 3283-3293.
8. Vilar J, Lalou C, Duong VH et al. Midkine is involved in kidney development and in its regulation by retinoids. J Am Soc Nephrol 2002; 13: 668-76. 9 Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. HB-GAM/pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture. Exp Cell Res 1998; 241: 171-180.
9. Dreyfus J, Brunet-de Carvalho N, Duprez D, Raulais D, Vigny M. HB-GAM/pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture. Exp Cell Res 1998; 241: 171-180.
10. Imai S, Kaksonen M, Raulo E et al. Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J Cell Biol 1998; 143: 1113-1128.
11. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204: 127-143.
12. Kadomatsu K, Hagihara M, Akhter S et al. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997; 75: 354-359.
13. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002; 132: 359-371.
14. Qi M, Ikematsu S, Maeda N et al. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 15868-15875.
15. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57: 1814-1819.
16. Ota K, Fujimori H, Ueda M et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer 2008; 99: 655-662.
17. Aridome K, Tsutsui J, Takao S et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655-661.
18. Ye C, Qi M, Fan QW et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999; 79: 179-184.
19. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 2000; 124:848-852.
20. Kato M, Shinozawa T, Kato S, Endo K, Terada T. Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. Liver 2000; 20: 216-221.
21. Garver RI Jr, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993; 9: 463-466.
22. Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol 2000; 13: 1060-1065.
23. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56:2515-2518.
24. Moon HS, Park WI, Sung SH et al. Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Oncol 2003; 88: 289-297.
25. Nakanishi T, Kadomatsu K, Okamoto T, Tomoda Y, Muramatsu T. Expression of midkine and pleiotropin in ovarian tumors. Obstet Gynecol 1997; 90: 285-290.
26. Konishi N, Nakamura M, Nakaoka S et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57: 253-257.
27. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584-1590.
28. Miyashiro I, Kaname T, Shin E et al. Midkine expression in human breast cancers: expression of truncated form. Breast Cancer Res Treat 1997; 43: 1-6.
29. Nakagawara A, Milbrandt J, Muramatsu T et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995; 55:1792-1797.
30. Mishima K, Asai A, Kadomatsu K et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997; 233: 29-32.
31. Mashour GA, Ratner N, Khan GA et al. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20: 97-105.
32. Takei Y, Kadomatsu K, Matsuo S et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61: 8486-8491.
33. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006; 107: 864-873.
34. Wang Q, Huang Y, Ni Y, Wang H, Hou Y. siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization. J Biomed Sci 2007; 14: 783-795.
35. Ikematsu S, Yano A, Aridome K et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000; 83: 701-706.
36. Krzystek-Korpacka M, Matusiewicz M, Diakowska D et al. Serum midkine depends on lymph node involvement and correlates with circulating VEGFC in oesophageal squamous cell carcinoma. Biomarkers 2007; 12: 403-413.
37. Muramatsu H, Song XJ, Koide N et al. Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. J Biochem 1996; 119: 1171-1175.
38. Obata Y, Kikuchi S, Lin Y et al. Serum midkine concentrations and gastric cancer. Cancer Sci 2005; 96: 54-56.
39. Shimada H, Nabeya Y, Tagawa M et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-632.
40. Shimada H, Nabeya Y, Okazumi S et al. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep 2003; 10: 411-414.
41. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
42. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
43. Yamamoto Y, Ibusuki M, Okumura Y et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008; 110: 465-475.
44. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16: 5-26.
45. Trudeau ME, Pritchard KI, Chapman J-AW et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment 2005; 89: 35-45.
46. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
47. Narita T, Funahashi H, Satoh Y, Imai T, Takagi H. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer. J Surg Oncol 1993; 54: 5-8.